Axogen（LT3）株式概要アクソジェン社は、その子会社とともに、末梢神経の再生と修復のための技術を開発し、世界中で商業化している。 詳細LT3 ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長4/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間71.95%増加すると予測されています アナリストらは、株価が24.2%上昇するだろうとほぼ一致している。 リスク分析過去3か月間に大規模なインサイダー売却が発生 過去1年間で株主の希薄化が進んだ German市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るLT3 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€34.89140.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-32m490m2016201920222025202620282031Revenue US$490.3mEarnings US$65.9mAdvancedSet Fair ValueView all narrativesAxogen, Inc. 競合他社Carl Zeiss MeditecSymbol: XTRA:AFXMarket cap: €2.3bDrägerwerk KGaASymbol: XTRA:DRW3Market cap: €1.5bEckert & ZieglerSymbol: XTRA:EUZMarket cap: €939.9mOttobock SE KGaASymbol: XTRA:OBCKMarket cap: €3.6b価格と性能株価の高値、安値、推移の概要Axogen過去の株価現在の株価US$34.8952週高値US$37.5952週安値US$7.85ベータ1.171ヶ月の変化11.65%3ヶ月変化18.67%1年変化263.44%3年間の変化328.10%5年間の変化110.18%IPOからの変化352.29%最新ニュースお知らせ • May 01Axogen, Inc., Annual General Meeting, Jun 23, 2026Axogen, Inc., Annual General Meeting, Jun 23, 2026.お知らせ • Apr 30Axogen, Inc. Provides Earnings Guidance for the Full Year 2026Axogen, Inc. provided earnings guidance for the full year 2026. For the period, The company expects 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to 76%.お知らせ • Apr 14Axogen, Inc. to Report Q1, 2026 Results on Apr 28, 2026Axogen, Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 28, 2026お知らせ • Feb 24Axogen, Inc. Provides Earnings Guidance for the Year 2026Axogen, Inc. provided earnings guidance for the year 2026. For the year,company expected revenue growth to be at least 18%, or $265.7 million, for the full-year and gross margin to be in the range of 74% to 76%.お知らせ • Feb 10Axogen, Inc. to Report Q4, 2025 Results on Feb 24, 2026Axogen, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 24, 2026お知らせ • Jan 22+ 1 more updateAxogen, Inc. has filed a Follow-on Equity Offering in the amount of $85 million.Axogen, Inc. has filed a Follow-on Equity Offering in the amount of $85 million. Security Name: Common Stock Security Type: Common Stock最新情報をもっと見るRecent updatesお知らせ • May 01Axogen, Inc., Annual General Meeting, Jun 23, 2026Axogen, Inc., Annual General Meeting, Jun 23, 2026.お知らせ • Apr 30Axogen, Inc. Provides Earnings Guidance for the Full Year 2026Axogen, Inc. provided earnings guidance for the full year 2026. For the period, The company expects 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to 76%.お知らせ • Apr 14Axogen, Inc. to Report Q1, 2026 Results on Apr 28, 2026Axogen, Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 28, 2026お知らせ • Feb 24Axogen, Inc. Provides Earnings Guidance for the Year 2026Axogen, Inc. provided earnings guidance for the year 2026. For the year,company expected revenue growth to be at least 18%, or $265.7 million, for the full-year and gross margin to be in the range of 74% to 76%.お知らせ • Feb 10Axogen, Inc. to Report Q4, 2025 Results on Feb 24, 2026Axogen, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 24, 2026お知らせ • Jan 22+ 1 more updateAxogen, Inc. has filed a Follow-on Equity Offering in the amount of $85 million.Axogen, Inc. has filed a Follow-on Equity Offering in the amount of $85 million. Security Name: Common Stock Security Type: Common Stockお知らせ • Jan 13Axogen, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2025Axogen, Inc. provided preliminary unaudited earnings guidance for the fourth quarter and full year of 2025. For the quarter, the company expects revenue to be approximately $59.9 million, which represents a 21.3% increase over the fourth quarter of 2024, driven by solid performance across the product portfolio. For the full year, the company expects revenue to be approximately $225.2 million, which represents a 20.2% increase over the full-year of 2024.お知らせ • Dec 04Axogen, Inc. Announces Fda Approval of Biologics License Application for Avance®Axogen, Inc. announced that the U.S. Food and Drug Administration (the "FDA") has approved the Biologics License Application ("BLA") for AVANCE® (acellular nerve allograft-arwx). Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities. The indications for sensory nerve discontinuities >25mm and for mixed and motor nerve discontinuities were approved under FDA's Accelerated Approval pathway based on the effect on static two-point discrimination in sensory nerve gaps 25mm, which provided empirical evidence to reasonably predict clinical benefit given similarities in pathophysiology and anticipated therapeutic effects. Continued approval for these indications depends on verification and description of clinical benefit in confirmatory studies. The approved BLA and successful transition of Avance to a biologic regulatory framework should give all stakeholders the assurance that Avance has been rigorously evaluated and determined to be safe, pure, and potent for its intended use, and that its benefits outweigh its known or potential risks. Commercial availability of the licensed Avance product is expected early in the second quarter of 2026. In the timeframe, Avance remains available under the current tissue framework. Avance remains available under the currently tissue framework. Indications: AVANCE® is an a cellular nerve scaffold indicated for the treatment of adult and adult and pediatric patients aged one month and older with: Sensory nerve discontinuity (25mm); Sensory nerve discontinuity (>25mm); Approved under accelerated approval based on static two-point discrimination (s2PD) at 12 months in sensory nerve gaps 25 mm, which reasonably predicts clinical benefit. Continued approval is contingent upon confirmatory clinical trial results. Mixed and motor nerve discontinuity; Approved under accelerated approved based on s2PD outcomes in sensory nerve gaps 25 mm; continued approval is contingent upon confirmatoryclinical trial results. Mixed and motor spinal discontinuity; Approved under accelerate approval based on s2PD outcomes In addition, the company has approved the Biologics license Application for AVANCE® (ACllular nerve allograft-ARwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguards Nerve Protector™, Axoguard HA+ Nerve Protector™, and Avive+ Soft Tissue Matrix™. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries.お知らせ • Oct 29Axogen, Inc. Raises Earnings Guidance for the Year 2025Axogen, Inc. raised earnings guidance for the year 2025. For the year, company raised revenue guidance to at least 19% growth, or $222.8 million for the full year. Company continued to expect gross margin for the year to be in the range of 73% to 75%.お知らせ • Oct 15Axogen, Inc. to Report Q3, 2025 Results on Oct 29, 2025Axogen, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 29, 2025お知らせ • Aug 25Axogen, Inc. Provides Update on FDA Review Timeline for Avance Nerve GraftAxogen, Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance®? Nerve Graft by three months to December 5, 2025. On August 22, 2025, the Company received a communication from the FDA indicating that the information submitted by the Company in response to an FDA information request, which included substantial new manufacturing and facility data not previously reviewed by the Agency, was deemed a Major Amendment to its BLA. Under FDA guidelines, this designation allows for additional time to review the submission. As a result, the FDA has extended the PDUFA goal date to December 5, 2025. The FDA also informed the Company that it now anticipates providing feedback on product labeling in November 2025, consistent with PDUFA review procedures.お知らせ • Aug 05Axogen, Inc. Raises Earnings Guidance for the Year 2025Axogen, Inc. raised earnings guidance for the year 2025 . For the year, company raising revenue guidance to at least 17% growth, or $219 million for the full year. We continue to expect gross margin for the year to be in the range of 73% to 75%.お知らせ • Jul 23Axogen, Inc. to Report Q2, 2025 Results on Aug 05, 2025Axogen, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 05, 2025お知らせ • May 08+ 1 more updateAxogen, Inc. Maintains Earnings Guidance for the Year 2025Axogen, Inc. maintained earnings guidance for the year 2025. The company is maintaining the company's full year revenue growth guidance in the range of 15% to 17% and continue to expect gross margin to be in the range of 73% to 75%. This includes one-time costs, mainly related to the anticipated BLA approval, impacting gross margin by approximately 1%.お知らせ • May 01Axogen, Inc., Annual General Meeting, Jun 18, 2025Axogen, Inc., Annual General Meeting, Jun 18, 2025.お知らせ • Apr 24Axogen, Inc. to Report Q1, 2025 Results on May 08, 2025Axogen, Inc. announced that they will report Q1, 2025 results Pre-Market on May 08, 2025お知らせ • Feb 26AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2025AxoGen, Inc. provided earnings guidance for the fiscal year 2025. For the year, the company expects revenue growth to be in the range of 15% to 17%.お知らせ • Jan 11Axogen, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2024Axogen, Inc. provided revenue guidance for the fourth quarter and full year 2024. For the quarter, the company's revenue is expected to be approximately $49.4 million, which represents a 15.1% increase over the fourth quarter of 2023 driven by solid performance across the product portfolio. Full-year 2024 revenue is expected to be approximately $187.3 million, which represents a 17.8% increase over the full-year of 2023.お知らせ • Jan 10Axogen, Inc. to Report Q4, 2024 Results on Mar 04, 2025Axogen, Inc. announced that they will report Q4, 2024 results on Mar 04, 2025New Risk • Nov 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).Reported Earnings • Nov 09Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.095 loss in 3Q 2023)Third quarter 2024 results: US$0.042 loss per share (improved from US$0.095 loss in 3Q 2023). Revenue: US$48.6m (up 18% from 3Q 2023). Net loss: US$1.86m (loss narrowed 55% from 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 08Axogen, Inc. Maintains Earnings Guidance for 2024Axogen, Inc. maintained earnings guidance for 2024. For the period, the company expects revenue in the range of $182 million to $186 million.Breakeven Date Change • Nov 07No longer forecast to breakevenThe 6 analysts covering Axogen no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.74m in 2025. New consensus forecast suggests the company will make a loss of US$4.30m in 2026.お知らせ • Oct 24Axogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024Axogen, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 07, 2024Breakeven Date Change • Oct 15Forecast to breakeven in 2025The 6 analysts covering Axogen expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$493.3k in 2025. Average annual earnings growth of 79% is required to achieve expected profit on schedule.お知らせ • Aug 10+ 1 more updateAxogen, Inc. Announces Chief Executive Officer ChangesAxogen, Inc. announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for nine months. The move aligns the executive team with the Companys needs going forward as Axogen focuses on commercial expansion, broad-based revenue growth, and driving toward sustainable positive cash flow and profitability. Mr. Dale has over 30 years of experience leading transformative, high-technology medical device companies in the cardiovascular, neuromodulation, diabetes, and electrophysiology markets. His past executive leadership roles span both public and private medical device companies.New Risk • Aug 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 7.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$5.9m net loss in 2 years).Reported Earnings • Aug 09Second quarter 2024 earnings released: US$0.044 loss per share (vs US$0.15 loss in 2Q 2023)Second quarter 2024 results: US$0.044 loss per share (improved from US$0.15 loss in 2Q 2023). Revenue: US$47.9m (up 26% from 2Q 2023). Net loss: US$1.92m (loss narrowed 71% from 2Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.お知らせ • Aug 08AxoGen, Inc. Updates Earnings Guidance for the Full Year 2024AxoGen, Inc. updated earnings guidance for the full year 2024. For the year, the company increased annual revenue guidance to the range of $182 million to $186 million.お知らせ • Jul 23AxoGen, Inc. to Report Q2, 2024 Results on Aug 08, 2024AxoGen, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024Breakeven Date Change • Jul 02Forecast breakeven date pushed back to 2026The 6 analysts covering AxoGen previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 49% per year to 2025. The company is expected to make a profit of US$17.7m in 2026. Average annual earnings growth of 84% is required to achieve expected profit on schedule.お知らせ • Jun 24Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue MatrixAxogen, Inc. announced the launch of its newest product, Avive+ Soft Tissue Matrix. Avive+ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product. Nerve protection represents approximately $800 million of the overall nerve repair market and covers a wide range of injuries and defects including carpal and cubital tunnel syndromes, crush injuries, and other non-transected traumatic nerve injuries. The diversity of these injury types and their anatomical locations present unique challenges and Axogen is committed to optimizing outcomes for patients, using its targeted portfolio of solutions to address the needs of each injury type, and the healing process. Avive+ Soft Tissue Matrix complements the Company’s existing portfolio of nerve protection products, which includes Axoguard Nerve Protector® and Axoguard HA+ Nerve Protector.Breakeven Date Change • Jun 16Forecast breakeven date moved forward to 2025The 5 analysts covering AxoGen previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 16% to 2024. The company is expected to make a profit of US$5.74m in 2025. Average annual earnings growth of 97% is required to achieve expected profit on schedule.Breakeven Date Change • May 31Forecast breakeven date moved forward to 2025The 5 analysts covering AxoGen previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 16% to 2024. The company is expected to make a profit of US$5.74m in 2025. Average annual earnings growth of 97% is required to achieve expected profit on schedule.お知らせ • May 03Axogen, Inc. Provides Revenue Guidance for the Year 2024AxoGen, Inc. provided revenue guidance for the year 2024. The company maintained its full year guidance with 2024 revenue in the range of $177 million to $181 million, which represents a growth rate of approximately 11% to 14%.Reported Earnings • May 02First quarter 2024 earnings released: US$0.15 loss per share (vs US$0.17 loss in 1Q 2023)First quarter 2024 results: US$0.15 loss per share (improved from US$0.17 loss in 1Q 2023). Revenue: US$41.4m (up 13% from 1Q 2023). Net loss: US$6.64m (loss narrowed 6.2% from 1Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Apr 30Axogen Announces First Surgical Implants of Avive+ Soft Tissue MatrixAxogen, Inc. announced the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™?. Avive+ Soft Tissue matrix™? is a resorbable, multi-layer, placenta-based allograft that provides temporary protection and tissue separation during the critical phase of healing for nerves. Avive+ is processed and distributed as a 361 tissue product in accordance with U.S. Food and Drug Administration (FDA) Good Tissue Practice under 21 CFR part 1271 regulations. The nerve protection category covers a wide range of injuries and defects, including nerve compression, crush, complex traumatic injuries, and surgical exposures. The diversity of these injury types and their anatomical locations present unique challenges for both the surgeon and the patient. To optimize recovery, Axogen provides solutions to adequately address the nerve and the surrounding environment throughout the healing process. Physical damage to a peripheral nerve, or the inability to properly connect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance®? Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging terminated peripheral nerve without the comorbidities associated with a second surgical site; Avive+ Soft TissueMatrix™?, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue repair; Axoguard Nerve Connector®?, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerved Protector®?, a porcines submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™?, a porcine Submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap®?, a porCine submucosa ECM products used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.お知らせ • Apr 26AxoGen, Inc., Annual General Meeting, Jun 05, 2024AxoGen, Inc., Annual General Meeting, Jun 05, 2024, at 08:00 US Eastern Standard Time. Agenda: To elect nine members to company board of directors to hold office for the ensuing year and until their successors are elected and qualified; to ratify the selection of Deloitte & Touche LLP as company independent registered public accounting firm for the year ending December 31, 2024; to approve the Axogen, Inc. third Amended and Restated 2019 long-term incentive plan to increase the number of shares authorized for issuance thereunder from 8,000,000 to 10,500,000; to consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof; and to consider other matters.お知らせ • Apr 17AxoGen, Inc. to Report Q1, 2024 Results on May 02, 2024AxoGen, Inc. announced that they will report Q1, 2024 results Pre-Market on May 02, 2024New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Significant insider selling over the past 3 months (€499k sold).Recent Insider Transactions • Mar 10Vice President of Operations recently sold €293k worth of stockOn the 7th of March, Michael Donovan sold around 36k shares on-market at roughly €8.06 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.お知らせ • Mar 10AxoGen, Inc. Announces Executive ChangesAngelo Scopelianos notified Axogen, Inc. of his intention to resign as the Company's Chief Research and Development Officer no later than March 31, 2024. Mr. Scopelianos will provide transition services as a consultant for a period commencing on the Separation Date and ending on December 31, 2024. The Consulting Period may be extended further upon mutual agreement of the Company and Mr. Scopelianos and may be terminated by the Company for cause. Mr. Scopelianos' product development responsibilities will be assumed by Ms. Stacy Arnold, Vice President of Product Development and Clinical Research, who is not an executive officer but is a member of the executive team and reports directly to the Company's CEO, Karen Zaderej.New Risk • Mar 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Significant insider selling over the past 3 months (€87k sold).お知らせ • Mar 06AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024AxoGen, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenue to be in the range of $177 million to $181 million, which represents an annual growth rate of approximately 11% to 14%.Reported Earnings • Mar 05Full year 2023 earnings released: US$0.51 loss per share (vs US$0.69 loss in FY 2022)Full year 2023 results: US$0.51 loss per share (improved from US$0.69 loss in FY 2022). Revenue: US$159.0m (up 15% from FY 2022). Net loss: US$21.7m (loss narrowed 25% from FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2026The 5 analysts covering AxoGen previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$25.3m in 2026. Average annual earnings growth of 55% is required to achieve expected profit on schedule.お知らせ • Jan 19Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical StudyAxogen, Inc. announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value <0.05). Additional data analysis found that over the 12-month course of follow-up, the Axoguard Nerve Cap group demonstrated statistical superiority for reduction in the total pain reported by participants compared to the standard-of-care neurectomy group (p-value <0.05).お知らせ • Jan 05+ 5 more updatesAxogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025Axogen, Inc. announced that Chief Executive Officer (CEO) Karen Zaderej plans to retire from the Company by January 2025. The Company’s Board of Directors will retain an executive recruitment firm to manage a search for her successor. When a new CEO is in place, Ms. Zaderej will step down from her executive post and Board duties and continue as a consultant to Axogen for an additional nine months to support the leadership transition and the submission process of the Biologics License Application (BLA) for Avance® Nerve Graft. While the transition is planned to be no later than Jan. 5, 2025, it could occur sooner depending on the timing of a new CEO appointment. Ms. Zaderej has led the transformation of Axogen from a small start-up company to a category leader in the growing market of nerve repair. As one of Axogen’s first employees, Ms. Zaderej initially oversaw the Company’s sales and marketing function before moving into the role of Chief Operating Officer and then CEO in 2010. Under her leadership, Axogen has built awareness of the patient quality of life impact related to nerve damage and has created the market for nerve repair. She has driven the diversification of Axogen’s portfolio to address nerve connection, protection, and termination with multiple nerve repair product launches and has led the work to develop a unique regulatory strategy for Avance with a planned filing of a BLA in the second quarter of this year.お知らせ • Dec 27Axogen, Inc. Appoints Kathy Weiler to its Board of DirectorsAxogen, Inc. announced the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board’s Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. Weiler is the Executive Vice President, Chief Commercial and Growth Officer at Amwell. Weiler oversees the company’s growth strategy, driving strategic initiatives and leading business development, sales and account management, commercial enablement, marketing, and strategic and channel partnership teams. Prior to Amwell, Weiler served as Chief Consumer Officer at Optum, where she led consumerism across the enterprise. Preceding that, she was Chief Consumer Strategy Officer at UnitedHealth Group and the Chief Marketing and Experience Officer of Optum Health, leading marketing efforts for Optum Care and Optum’s Population Health Solutions, Complex Care Management, Medical Benefits Management, Behavioral Health, Prevention and Financial Services businesses. Weiler also served as Chief Marketing and Product Officer at Blue Cross and Blue Shield of Massachusetts, where she drove strategic growth and retention business objectives. Weiler spent her earlier career with multiple financial services organizations. She was Chief Marketing Officer of Fidelity Investments FAS business and held senior marketing leadership roles at BNY Mellon/Pershing and The Hartford. Weiler holds a B.A. from Bowdoin College and an M.A. in International Economics and Finance from Brandeis University.Recent Insider Transactions • Dec 14Insider recently sold €87k worth of stockOn the 11th of December, Peter Mariani sold around 13k shares on-market at roughly €6.99 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €317k more than they bought in the last 12 months.お知らせ • Dec 06AxoGen, Inc. Announces CFO ChangesAxogen, Inc. announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately. A senior finance executive with more than 20 years of experience primarily in the life sciences industry, he replaces Peter Mariani, who will depart Axogen following a brief transition period. The move aligns the executive team with the Company’s financial management and investor relations needs going forward as Axogen focuses on continued revenue growth across both business categories while driving toward being cash flow positive and profitable. Mr. Naor has diverse finance and operations leadership experience with public and private pharma, life sciences, and medtech companies worldwide. In previous roles, he managed global organizations with up to $2.5 billion in sales and built top-performing finance & accounting, IR, legal, contracting & pricing, IT, and big data analytics functions. Mr. Naor has served as the CFO of Arbor Pharmaceuticals and supported its strategic pivot. He was also the CFO U.S./Americas of Mölnlycke Healthcare, where he played a pivotal role in its growth and profitability improvement and was the founder of UCB’s global Portfolio Management and Resource Allocation function, as well as the company’s U.S. CFO. Earlier in his career, he held several finance leadership positions with AstraZeneca, served as a financial consultant and investment banker, worked as an auditor with KPMG, and practiced commercial law. He continues to advise and serve as a board member for emerging life sciences and technology companies. Mr. Naor holds a Master of Business Administration from IMD Business School in Switzerland, a master’s degree in law (LL.M.) from Hamburg University in Germany, and bachelor’s degrees in law (LL.B.) and in accounting from the Tel-Aviv University in Israel. Mr. Naor is also a CFA charter holder.Reported Earnings • Nov 09Third quarter 2023 earnings released: US$0.095 loss per share (vs US$0.10 loss in 3Q 2022)Third quarter 2023 results: US$0.095 loss per share (improved from US$0.10 loss in 3Q 2022). Revenue: US$41.3m (up 12% from 3Q 2022). Net loss: US$4.09m (loss narrowed 5.3% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • Nov 08Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023AxoGen, Inc. provided revenue guidance for the full-year 2023. For the year, the company maintaining full-year 2023 revenue guidance in the range of $154 million to $159 million, which represents annual growth of 11% - 15%.お知らせ • Oct 19AxoGen, Inc. to Report Q3, 2023 Results on Nov 07, 2023AxoGen, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023お知らせ • Sep 06Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve ProtectorAxogen, Inc. announced the full launch of Axoguard HA+ Nerve Protector. Axoguard HA+ Nerve Protector is a proprietary nerve protection device uniquely designed to provide both short- and long-term protection for peripheral nerve injuries. The device is comprised of a processed porcine submucosa extracellular matrix base layer with a hyaluronate-alginate gel coating. The gel layer facilitates enhanced nerve gliding to aid in minimizing soft tissue attachments, while the base layer is remodeled into a long-term protective tissue layer. The nerve protection category covers a wide range of injuries and defects, including nerve compression, crush, and complex traumatic injuries. The diversity of these injury types and their anatomical locations present unique challenges for both the surgeon and the patient. Optimizing outcomes requires targeted solutions to adequately address the nerve and the surrounding environment throughout the healing process.Recent Insider Transactions • Aug 20Independent Director recently bought €56k worth of stockOn the 16th of August, Guido Neels bought around 10k shares on-market at roughly €5.60 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €349k more in shares than they bought in the last 12 months.New Risk • Aug 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Significant insider selling over the past 3 months (€405k sold).お知らせ • Aug 09Axogen, Inc. Provides Revenue Guidance for the Year 2023AxoGen, Inc. Provided revenue guidance for the year 2023. For the full year, the company provides revenue in the range of $154 million to $159 million which represents annual growth of 11% - 15%.Breakeven Date Change • Aug 08Forecast to breakeven in 2025The 5 analysts covering AxoGen expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 22% per year to 2024. The company is expected to make a profit of US$15.0m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.お知らせ • Jul 28+ 1 more updateAxoGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023AxoGen, Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2023Recent Insider Transactions • Jun 07Director recently sold €341k worth of stockOn the 1st of June, Gregory Freitag sold around 42k shares on-market at roughly €8.12 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €405k more than they bought in the last 12 months.Recent Insider Transactions • May 25Director recently sold €64k worth of stockOn the 23rd of May, Gregory Freitag sold around 7k shares on-market at roughly €8.56 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.お知らせ • May 10AxoGen, Inc. Provides Earnings Guidance for the Full-Year 2023AxoGen, Inc. provided earnings guidance for the full-year 2023. For the year, the company expects revenue to be in the range of $154 million to $159 million.Reported Earnings • May 10First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.27 loss in 1Q 2022)First quarter 2023 results: US$0.17 loss per share (improved from US$0.27 loss in 1Q 2022). Revenue: US$36.7m (up 18% from 1Q 2022). Net loss: US$7.07m (loss narrowed 38% from 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.Breakeven Date Change • Mar 28No longer forecast to breakevenThe 5 analysts covering AxoGen no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$13.6m in 2025. New consensus forecast suggests the company will make a loss of US$1.93m in 2025.Breakeven Date Change • Mar 16No longer forecast to breakevenThe 5 analysts covering AxoGen no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$13.6m in 2025. New consensus forecast suggests the company will make a loss of US$1.47m in 2025.Reported Earnings • Mar 15Full year 2022 earnings released: US$0.69 loss per share (vs US$0.66 loss in FY 2021)Full year 2022 results: US$0.69 loss per share (further deteriorated from US$0.66 loss in FY 2021). Revenue: US$138.6m (up 8.8% from FY 2021). Net loss: US$28.9m (loss widened 7.3% from FY 2021). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 6% per year.お知らせ • Feb 14Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing OfficerAxogen, Inc. announced the appointment of Jens Schroeder Kemp to the newly created role of Chief Marketing Officer. Kemp brings more than 20 years of strategic marketing, sales, and business development experience in high-growing medical technology. As a member of the Axogen executive leadership team, Kemp will report directly to Karen Zaderej, Chairman, CEO and President, and will oversee the development and execution of the company’s marketing strategies. Mr. Kemp most recently served as Vice President of Marketing for Ambu Inc, where he led Ambu’s marketing efforts to create the single use endoscopy market across multiple clinical applications. Following Ambu’s acquisition of King Systems in 2012, Mr. Kemp developed and scaled the US marketing function with new capabilities in health economics and market access, market development and digital marketing. Across more than 15 years at Ambu, he had multiple roles in business development and marketing, and served as a member of the Global Management Team. Prior to Ambu, Mr. Kemp was a management consultant at PERA (Production and Engineering Research Association), where his role included sales, marketing, and innovation strategies for medical device and renewable energy products. Previously, he was co-founder of an artificial intelligence decision support software company Mindgroup ApS. Mr. Kemp has a bachelor’s degree in business administration, and a master’s degree in international marketing and management, both from Copenhagen Business School.お知らせ • Jan 10+ 1 more updateAxoGen, Inc. to Report Q4, 2022 Results on Mar 14, 2023AxoGen, Inc. announced that they will report Q4, 2022 results on Mar 14, 2023Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 5 analysts covering AxoGen expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$9.65m in 2025. Average annual earnings growth of 56% is required to achieve expected profit on schedule.Reported Earnings • Nov 09Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.17 loss in 3Q 2021)Third quarter 2022 results: US$0.10 loss per share (improved from US$0.17 loss in 3Q 2021). Revenue: US$37.0m (up 18% from 3Q 2021). Net loss: US$4.32m (loss narrowed 40% from 3Q 2021). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Nov 09AxoGen, Inc. Updates Earnings Guidance for the Full Year 2022AxoGen, Inc. updated earnings guidance for the full year 2022. For the year, the company is narrowing the range of annual revenue guidance and expects revenue to be in the range of $137.5 million to $140.0 million versus the prior range of $135.0 million to $142.0 million. Full-year 2022 gross margin is expected to be above 80%.お知らせ • Nov 01Axogen, Inc. Announces Directorate ChangesAxogen, Inc. announced that effective December 13, 2022, Adrian Tyndall, M.D., MPH, FACEP has been appointed as an independent member to the company's board of directors and will serve on the Quality, Compliance, and Portfolio Management Committee. The company also announced that Mark Gold, M.D. a founding director, will retire from the board of directors on the Effective Date. Dr. Gold will continue to serve the Board of Directors until that time. Joseph "Adrian" Tyndall, MD, MPH, FACEP is a recognized leader in emergency medicine, educational leadership and research and is currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine. Previously, Dr. Tyndall spent more than 13 years as Professor, Emergency Medicine Department Chair, Trauma Researcher and Interim Dean and Associate Vice President at the University of Florida College of Medicine and UF Health. A graduate of the University of Maryland School of Medicine including the emergency medicine residency program at the University of Maryland Medical System, Dr. Tyndall received a master's degree in Health Services Management and Health Policy from Columbia University, and a bachelor's degree in Chemistry from The George Washington University. He is board-certified in emergency medicine by the American Board of Emergency Medicine and an American College of Emergency Physicians Fellow. Dr. Tyndall is the current President of the Society for Academic Emergency Medicine Foundation and was also recently elected to serve a two year term on the administrative board of the Council of Deans of the Association of American Medical Colleges (AAMC). He has researched and published on traumatic and ischemic brain injuries, is an editor for a leading emergency medicine reference textbook and is known worldwide in the field of emergency medicine.お知らせ • Oct 21AxoGen, Inc. to Report Q3, 2022 Results on Nov 08, 2022AxoGen, Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 08, 2022Reported Earnings • Aug 04Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.19 loss in 2Q 2021)Second quarter 2022 results: US$0.18 loss per share (up from US$0.19 loss in 2Q 2021). Revenue: US$34.5m (up 2.6% from 2Q 2021). Net loss: US$7.74m (loss narrowed 2.0% from 2Q 2021). Over the next year, revenue is forecast to grow 17%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 3% per year.お知らせ • Jul 19+ 2 more updatesEric Sandberg, Current Chief Commercial Officer Will Be Leaving AxoGen, IncAxoGen, Inc. announced that the company is making certain changes to its commercial organization designed to leverage the strength of its growing portfolio of clinical data and support innovation of advanced nerve repair solutions. As a result of these changes, the sales organization will report directly to Karen Zaderej, Axogen’s chairman, CEO, and president, and the company anticipates appointing a chief marketing officer in the coming months. Eric Sandberg, the Company’s current chief commercial officer will be leaving the organization effective July 19, 2022.お知らせ • Jul 12Axogen, Inc. Appoints William Burke to Board of DirectorsAxogen, Inc. announced that, effective July 11, 2022, William Burke has been appointed to its Board of Directors and will serve as chair of the Audit Committee. Mr. Burke is a recognized finance leader in the medical technology industry with more than 25 years of experience in senior leadership positions, including at Haemonetics, Medtronic, and Covidien. Burke was the executive vice president, chief financial officer of Haemonetics Corporation from August 2016 to June 2022 with responsibility for the global finance organization including investor relations. From July 2014 to July 2016, Burke served as chief integration officer and vice president, Integration for Medtronic plc and was a member of its executive committee. In that role, he was responsible for ensuring the successful integration of Medtronic with Covidien plc following its acquisition by Medtronic. Prior to joining Medtronic, Burke spent more than 20 years in finance and business development leadership roles at Covidien, including chief financial officer for Covidien Europe based in Zurich, vice president of Corporate Strategy and Portfolio Management and vice president of Financial Planning and Analysis. He also previously held key positions within Tyco Healthcare, including the financial controller of Valleylab, managing director of the Covidien Group in Switzerland, and international controller. He began his career as an auditor with KPMG. He currently serves on the board of directors of MiroMatrix. He received his Bachelor of Science degree in Business Administration from Bryant College.Reported Earnings • May 06First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 1Q 2021)First quarter 2022 results: US$0.27 loss per share (down from US$0.16 loss in 1Q 2021). Revenue: US$31.0m (flat on 1Q 2021). Net loss: US$11.5m (loss widened 72% from 1Q 2021). Over the next year, revenue is forecast to grow 13%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • May 05+ 1 more updateAxoGen, Inc. Provides Earnings Guidance for the Full Year of 2022AxoGen, Inc. provided earnings guidance for the full year of 2022. For the year, the company continues to expect 2022 revenue will be in the range of $135.0 million to $142.0 million. This represents approximately 10% to 15% growth over 2021 revenue excluding the impact of $4.1 million of Avive revenue in 2021. Full-year 2022 gross margin is expected to be above 80%.お知らせ • Apr 15AxoGen, Inc., Annual General Meeting, May 25, 2022AxoGen, Inc., Annual General Meeting, May 25, 2022, at 08:15 Eastern Daylight. Agenda: To consider electing eight members to board of directors to hold office for the ensuing year and until their successors are elected and qualified; to consider ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2022; to consider approving compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement; to consider amendments; and to consider similar matters.お知らせ • Apr 14AxoGen, Inc. to Report Q1, 2022 Results on May 04, 2022AxoGen, Inc. announced that they will report Q1, 2022 results After-Market on May 04, 2022お知らせ • Apr 03AxoGen, Inc. Announces Board ChangesOn March 29, 2022, Quentin S. Blackford notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Audit Committee and Compensation Committee, effective as of 11:59 PM EST on March 30, 2022. Mr. Blackford’s decision to resign was not associated with or attributable to any dispute or disagreement with the Company, its management or the Board on any matter relating to the Company’s operations, policies or practices, or otherwise. To fill the vacancies on the Board committees created by Mr. Blackford’s departure, the Board has, in each case, effective as of March 30, 2022 (i) appointed John H. Johnson to serve on the Audit Committee as its chair, and (ii) appointed Alan M. Levine to serve on the Compensation Committee.Reported Earnings • Feb 24Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.66 loss per share (down from US$0.59 loss in FY 2020). Revenue: US$127.4m (up 13% from FY 2020). Net loss: US$27.0m (loss widened 13% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • Jan 12AxoGen, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021AxoGen, Inc. provided earnings guidance for the fourth quarter and full year of 2021. Fourth quarter revenue is expected to be approximately $31.5 million, a 3% decrease compared to fourth-quarter 2020 revenue of $32.5 million.Management now expects 2021 revenue to be approximately $127.3 million and continues to expect full-year 2021.株主還元LT3DE Medical EquipmentDE 市場7D1.9%1.9%2.4%1Y263.4%-28.7%1.2%株主還元を見る業界別リターン: LT3過去 1 年間で-28.7 % の収益を上げたGerman Medical Equipment業界を上回りました。リターン対市場: LT3過去 1 年間で1.2 % の収益を上げたGerman市場を上回りました。価格変動Is LT3's price volatile compared to industry and market?LT3 volatilityLT3 Average Weekly Movement9.0%Medical Equipment Industry Average Movement6.1%Market Average Movement6.1%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%安定した株価: LT3の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: LT3の weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a622Michael Dalewww.axogeninc.comは、その子会社とともに、末梢神経の再生と修復のための技術を開発し、世界中で商業化している。同社の製品には、切断された末梢神経を二次手術部位に付随する合併症なしに橋渡しするための、生物学的に活性な既製加工ヒト神経移植片であるAvance Nerve Graft、切断された末梢神経を無張力で修復するためのブタ粘膜下層細胞外マトリックス（ECM）コアプテーション補助材であるAxoGuard Nerve Connectorなどがある；AxoGuard神経プロテクターは、損傷した末梢神経を包んで保護し、軟組織の癒着を防ぎながら神経の再建を補強するために使用されるブタ粘膜下層ECM製品であり、Axoguard HA+神経プロテクターは、末梢神経損傷に短期的および長期的な保護を提供するために設計されたヒアルロン酸アルギン酸ゲルコーティングを施した加工ブタ粘膜下層ECMベースレイヤーである。また、Axoguard Nerve Capはブタ粘膜下層ECM製品で、末梢神経の末端を保護し、神経を周囲の環境から分離することにより、有症状または有痛性の神経腫の発生を抑制する。同社は病院、手術センター、軍病院、形成再建外科医、整形外科医、形成手外科医、各種口腔顎顔面外科医に製品を提供している。本社はフロリダ州アラチュアにある。もっと見るAxogen, Inc. 基礎のまとめAxogen の収益と売上を時価総額と比較するとどうか。LT3 基礎統計学時価総額€1.87b収益（TTM）-€27.10m売上高(TTM)€205.15m9.1xP/Sレシオ-69.1xPER（株価収益率LT3 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計LT3 損益計算書（TTM）収益US$238.11m売上原価US$59.50m売上総利益US$178.61mその他の費用US$210.06m収益-US$31.45m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.59グロス・マージン75.01%純利益率-13.21%有利子負債／自己資本比率0%LT3 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 15:28終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Axogen, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Caitlin CroninCanaccord GenuityDavid TurkalyCitizens JMP Securities, LLCChristopher PasqualeGuggenheim Securities, LLC15 その他のアナリストを表示
お知らせ • May 01Axogen, Inc., Annual General Meeting, Jun 23, 2026Axogen, Inc., Annual General Meeting, Jun 23, 2026.
お知らせ • Apr 30Axogen, Inc. Provides Earnings Guidance for the Full Year 2026Axogen, Inc. provided earnings guidance for the full year 2026. For the period, The company expects 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to 76%.
お知らせ • Apr 14Axogen, Inc. to Report Q1, 2026 Results on Apr 28, 2026Axogen, Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 28, 2026
お知らせ • Feb 24Axogen, Inc. Provides Earnings Guidance for the Year 2026Axogen, Inc. provided earnings guidance for the year 2026. For the year,company expected revenue growth to be at least 18%, or $265.7 million, for the full-year and gross margin to be in the range of 74% to 76%.
お知らせ • Feb 10Axogen, Inc. to Report Q4, 2025 Results on Feb 24, 2026Axogen, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 24, 2026
お知らせ • Jan 22+ 1 more updateAxogen, Inc. has filed a Follow-on Equity Offering in the amount of $85 million.Axogen, Inc. has filed a Follow-on Equity Offering in the amount of $85 million. Security Name: Common Stock Security Type: Common Stock
お知らせ • May 01Axogen, Inc., Annual General Meeting, Jun 23, 2026Axogen, Inc., Annual General Meeting, Jun 23, 2026.
お知らせ • Apr 30Axogen, Inc. Provides Earnings Guidance for the Full Year 2026Axogen, Inc. provided earnings guidance for the full year 2026. For the period, The company expects 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to 76%.
お知らせ • Apr 14Axogen, Inc. to Report Q1, 2026 Results on Apr 28, 2026Axogen, Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 28, 2026
お知らせ • Feb 24Axogen, Inc. Provides Earnings Guidance for the Year 2026Axogen, Inc. provided earnings guidance for the year 2026. For the year,company expected revenue growth to be at least 18%, or $265.7 million, for the full-year and gross margin to be in the range of 74% to 76%.
お知らせ • Feb 10Axogen, Inc. to Report Q4, 2025 Results on Feb 24, 2026Axogen, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 24, 2026
お知らせ • Jan 22+ 1 more updateAxogen, Inc. has filed a Follow-on Equity Offering in the amount of $85 million.Axogen, Inc. has filed a Follow-on Equity Offering in the amount of $85 million. Security Name: Common Stock Security Type: Common Stock
お知らせ • Jan 13Axogen, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2025Axogen, Inc. provided preliminary unaudited earnings guidance for the fourth quarter and full year of 2025. For the quarter, the company expects revenue to be approximately $59.9 million, which represents a 21.3% increase over the fourth quarter of 2024, driven by solid performance across the product portfolio. For the full year, the company expects revenue to be approximately $225.2 million, which represents a 20.2% increase over the full-year of 2024.
お知らせ • Dec 04Axogen, Inc. Announces Fda Approval of Biologics License Application for Avance®Axogen, Inc. announced that the U.S. Food and Drug Administration (the "FDA") has approved the Biologics License Application ("BLA") for AVANCE® (acellular nerve allograft-arwx). Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities. The indications for sensory nerve discontinuities >25mm and for mixed and motor nerve discontinuities were approved under FDA's Accelerated Approval pathway based on the effect on static two-point discrimination in sensory nerve gaps 25mm, which provided empirical evidence to reasonably predict clinical benefit given similarities in pathophysiology and anticipated therapeutic effects. Continued approval for these indications depends on verification and description of clinical benefit in confirmatory studies. The approved BLA and successful transition of Avance to a biologic regulatory framework should give all stakeholders the assurance that Avance has been rigorously evaluated and determined to be safe, pure, and potent for its intended use, and that its benefits outweigh its known or potential risks. Commercial availability of the licensed Avance product is expected early in the second quarter of 2026. In the timeframe, Avance remains available under the current tissue framework. Avance remains available under the currently tissue framework. Indications: AVANCE® is an a cellular nerve scaffold indicated for the treatment of adult and adult and pediatric patients aged one month and older with: Sensory nerve discontinuity (25mm); Sensory nerve discontinuity (>25mm); Approved under accelerated approval based on static two-point discrimination (s2PD) at 12 months in sensory nerve gaps 25 mm, which reasonably predicts clinical benefit. Continued approval is contingent upon confirmatory clinical trial results. Mixed and motor nerve discontinuity; Approved under accelerated approved based on s2PD outcomes in sensory nerve gaps 25 mm; continued approval is contingent upon confirmatoryclinical trial results. Mixed and motor spinal discontinuity; Approved under accelerate approval based on s2PD outcomes In addition, the company has approved the Biologics license Application for AVANCE® (ACllular nerve allograft-ARwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguards Nerve Protector™, Axoguard HA+ Nerve Protector™, and Avive+ Soft Tissue Matrix™. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries.
お知らせ • Oct 29Axogen, Inc. Raises Earnings Guidance for the Year 2025Axogen, Inc. raised earnings guidance for the year 2025. For the year, company raised revenue guidance to at least 19% growth, or $222.8 million for the full year. Company continued to expect gross margin for the year to be in the range of 73% to 75%.
お知らせ • Oct 15Axogen, Inc. to Report Q3, 2025 Results on Oct 29, 2025Axogen, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 29, 2025
お知らせ • Aug 25Axogen, Inc. Provides Update on FDA Review Timeline for Avance Nerve GraftAxogen, Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance®? Nerve Graft by three months to December 5, 2025. On August 22, 2025, the Company received a communication from the FDA indicating that the information submitted by the Company in response to an FDA information request, which included substantial new manufacturing and facility data not previously reviewed by the Agency, was deemed a Major Amendment to its BLA. Under FDA guidelines, this designation allows for additional time to review the submission. As a result, the FDA has extended the PDUFA goal date to December 5, 2025. The FDA also informed the Company that it now anticipates providing feedback on product labeling in November 2025, consistent with PDUFA review procedures.
お知らせ • Aug 05Axogen, Inc. Raises Earnings Guidance for the Year 2025Axogen, Inc. raised earnings guidance for the year 2025 . For the year, company raising revenue guidance to at least 17% growth, or $219 million for the full year. We continue to expect gross margin for the year to be in the range of 73% to 75%.
お知らせ • Jul 23Axogen, Inc. to Report Q2, 2025 Results on Aug 05, 2025Axogen, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 05, 2025
お知らせ • May 08+ 1 more updateAxogen, Inc. Maintains Earnings Guidance for the Year 2025Axogen, Inc. maintained earnings guidance for the year 2025. The company is maintaining the company's full year revenue growth guidance in the range of 15% to 17% and continue to expect gross margin to be in the range of 73% to 75%. This includes one-time costs, mainly related to the anticipated BLA approval, impacting gross margin by approximately 1%.
お知らせ • May 01Axogen, Inc., Annual General Meeting, Jun 18, 2025Axogen, Inc., Annual General Meeting, Jun 18, 2025.
お知らせ • Apr 24Axogen, Inc. to Report Q1, 2025 Results on May 08, 2025Axogen, Inc. announced that they will report Q1, 2025 results Pre-Market on May 08, 2025
お知らせ • Feb 26AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2025AxoGen, Inc. provided earnings guidance for the fiscal year 2025. For the year, the company expects revenue growth to be in the range of 15% to 17%.
お知らせ • Jan 11Axogen, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2024Axogen, Inc. provided revenue guidance for the fourth quarter and full year 2024. For the quarter, the company's revenue is expected to be approximately $49.4 million, which represents a 15.1% increase over the fourth quarter of 2023 driven by solid performance across the product portfolio. Full-year 2024 revenue is expected to be approximately $187.3 million, which represents a 17.8% increase over the full-year of 2023.
お知らせ • Jan 10Axogen, Inc. to Report Q4, 2024 Results on Mar 04, 2025Axogen, Inc. announced that they will report Q4, 2024 results on Mar 04, 2025
New Risk • Nov 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
Reported Earnings • Nov 09Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.095 loss in 3Q 2023)Third quarter 2024 results: US$0.042 loss per share (improved from US$0.095 loss in 3Q 2023). Revenue: US$48.6m (up 18% from 3Q 2023). Net loss: US$1.86m (loss narrowed 55% from 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 08Axogen, Inc. Maintains Earnings Guidance for 2024Axogen, Inc. maintained earnings guidance for 2024. For the period, the company expects revenue in the range of $182 million to $186 million.
Breakeven Date Change • Nov 07No longer forecast to breakevenThe 6 analysts covering Axogen no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.74m in 2025. New consensus forecast suggests the company will make a loss of US$4.30m in 2026.
お知らせ • Oct 24Axogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024Axogen, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 07, 2024
Breakeven Date Change • Oct 15Forecast to breakeven in 2025The 6 analysts covering Axogen expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$493.3k in 2025. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
お知らせ • Aug 10+ 1 more updateAxogen, Inc. Announces Chief Executive Officer ChangesAxogen, Inc. announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for nine months. The move aligns the executive team with the Companys needs going forward as Axogen focuses on commercial expansion, broad-based revenue growth, and driving toward sustainable positive cash flow and profitability. Mr. Dale has over 30 years of experience leading transformative, high-technology medical device companies in the cardiovascular, neuromodulation, diabetes, and electrophysiology markets. His past executive leadership roles span both public and private medical device companies.
New Risk • Aug 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 7.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$5.9m net loss in 2 years).
Reported Earnings • Aug 09Second quarter 2024 earnings released: US$0.044 loss per share (vs US$0.15 loss in 2Q 2023)Second quarter 2024 results: US$0.044 loss per share (improved from US$0.15 loss in 2Q 2023). Revenue: US$47.9m (up 26% from 2Q 2023). Net loss: US$1.92m (loss narrowed 71% from 2Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
お知らせ • Aug 08AxoGen, Inc. Updates Earnings Guidance for the Full Year 2024AxoGen, Inc. updated earnings guidance for the full year 2024. For the year, the company increased annual revenue guidance to the range of $182 million to $186 million.
お知らせ • Jul 23AxoGen, Inc. to Report Q2, 2024 Results on Aug 08, 2024AxoGen, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024
Breakeven Date Change • Jul 02Forecast breakeven date pushed back to 2026The 6 analysts covering AxoGen previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 49% per year to 2025. The company is expected to make a profit of US$17.7m in 2026. Average annual earnings growth of 84% is required to achieve expected profit on schedule.
お知らせ • Jun 24Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue MatrixAxogen, Inc. announced the launch of its newest product, Avive+ Soft Tissue Matrix. Avive+ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product. Nerve protection represents approximately $800 million of the overall nerve repair market and covers a wide range of injuries and defects including carpal and cubital tunnel syndromes, crush injuries, and other non-transected traumatic nerve injuries. The diversity of these injury types and their anatomical locations present unique challenges and Axogen is committed to optimizing outcomes for patients, using its targeted portfolio of solutions to address the needs of each injury type, and the healing process. Avive+ Soft Tissue Matrix complements the Company’s existing portfolio of nerve protection products, which includes Axoguard Nerve Protector® and Axoguard HA+ Nerve Protector.
Breakeven Date Change • Jun 16Forecast breakeven date moved forward to 2025The 5 analysts covering AxoGen previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 16% to 2024. The company is expected to make a profit of US$5.74m in 2025. Average annual earnings growth of 97% is required to achieve expected profit on schedule.
Breakeven Date Change • May 31Forecast breakeven date moved forward to 2025The 5 analysts covering AxoGen previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 16% to 2024. The company is expected to make a profit of US$5.74m in 2025. Average annual earnings growth of 97% is required to achieve expected profit on schedule.
お知らせ • May 03Axogen, Inc. Provides Revenue Guidance for the Year 2024AxoGen, Inc. provided revenue guidance for the year 2024. The company maintained its full year guidance with 2024 revenue in the range of $177 million to $181 million, which represents a growth rate of approximately 11% to 14%.
Reported Earnings • May 02First quarter 2024 earnings released: US$0.15 loss per share (vs US$0.17 loss in 1Q 2023)First quarter 2024 results: US$0.15 loss per share (improved from US$0.17 loss in 1Q 2023). Revenue: US$41.4m (up 13% from 1Q 2023). Net loss: US$6.64m (loss narrowed 6.2% from 1Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Apr 30Axogen Announces First Surgical Implants of Avive+ Soft Tissue MatrixAxogen, Inc. announced the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™?. Avive+ Soft Tissue matrix™? is a resorbable, multi-layer, placenta-based allograft that provides temporary protection and tissue separation during the critical phase of healing for nerves. Avive+ is processed and distributed as a 361 tissue product in accordance with U.S. Food and Drug Administration (FDA) Good Tissue Practice under 21 CFR part 1271 regulations. The nerve protection category covers a wide range of injuries and defects, including nerve compression, crush, complex traumatic injuries, and surgical exposures. The diversity of these injury types and their anatomical locations present unique challenges for both the surgeon and the patient. To optimize recovery, Axogen provides solutions to adequately address the nerve and the surrounding environment throughout the healing process. Physical damage to a peripheral nerve, or the inability to properly connect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance®? Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging terminated peripheral nerve without the comorbidities associated with a second surgical site; Avive+ Soft TissueMatrix™?, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue repair; Axoguard Nerve Connector®?, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerved Protector®?, a porcines submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™?, a porcine Submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap®?, a porCine submucosa ECM products used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.
お知らせ • Apr 26AxoGen, Inc., Annual General Meeting, Jun 05, 2024AxoGen, Inc., Annual General Meeting, Jun 05, 2024, at 08:00 US Eastern Standard Time. Agenda: To elect nine members to company board of directors to hold office for the ensuing year and until their successors are elected and qualified; to ratify the selection of Deloitte & Touche LLP as company independent registered public accounting firm for the year ending December 31, 2024; to approve the Axogen, Inc. third Amended and Restated 2019 long-term incentive plan to increase the number of shares authorized for issuance thereunder from 8,000,000 to 10,500,000; to consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof; and to consider other matters.
お知らせ • Apr 17AxoGen, Inc. to Report Q1, 2024 Results on May 02, 2024AxoGen, Inc. announced that they will report Q1, 2024 results Pre-Market on May 02, 2024
New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Significant insider selling over the past 3 months (€499k sold).
Recent Insider Transactions • Mar 10Vice President of Operations recently sold €293k worth of stockOn the 7th of March, Michael Donovan sold around 36k shares on-market at roughly €8.06 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
お知らせ • Mar 10AxoGen, Inc. Announces Executive ChangesAngelo Scopelianos notified Axogen, Inc. of his intention to resign as the Company's Chief Research and Development Officer no later than March 31, 2024. Mr. Scopelianos will provide transition services as a consultant for a period commencing on the Separation Date and ending on December 31, 2024. The Consulting Period may be extended further upon mutual agreement of the Company and Mr. Scopelianos and may be terminated by the Company for cause. Mr. Scopelianos' product development responsibilities will be assumed by Ms. Stacy Arnold, Vice President of Product Development and Clinical Research, who is not an executive officer but is a member of the executive team and reports directly to the Company's CEO, Karen Zaderej.
New Risk • Mar 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Significant insider selling over the past 3 months (€87k sold).
お知らせ • Mar 06AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024AxoGen, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenue to be in the range of $177 million to $181 million, which represents an annual growth rate of approximately 11% to 14%.
Reported Earnings • Mar 05Full year 2023 earnings released: US$0.51 loss per share (vs US$0.69 loss in FY 2022)Full year 2023 results: US$0.51 loss per share (improved from US$0.69 loss in FY 2022). Revenue: US$159.0m (up 15% from FY 2022). Net loss: US$21.7m (loss narrowed 25% from FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2026The 5 analysts covering AxoGen previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$25.3m in 2026. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
お知らせ • Jan 19Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical StudyAxogen, Inc. announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value <0.05). Additional data analysis found that over the 12-month course of follow-up, the Axoguard Nerve Cap group demonstrated statistical superiority for reduction in the total pain reported by participants compared to the standard-of-care neurectomy group (p-value <0.05).
お知らせ • Jan 05+ 5 more updatesAxogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025Axogen, Inc. announced that Chief Executive Officer (CEO) Karen Zaderej plans to retire from the Company by January 2025. The Company’s Board of Directors will retain an executive recruitment firm to manage a search for her successor. When a new CEO is in place, Ms. Zaderej will step down from her executive post and Board duties and continue as a consultant to Axogen for an additional nine months to support the leadership transition and the submission process of the Biologics License Application (BLA) for Avance® Nerve Graft. While the transition is planned to be no later than Jan. 5, 2025, it could occur sooner depending on the timing of a new CEO appointment. Ms. Zaderej has led the transformation of Axogen from a small start-up company to a category leader in the growing market of nerve repair. As one of Axogen’s first employees, Ms. Zaderej initially oversaw the Company’s sales and marketing function before moving into the role of Chief Operating Officer and then CEO in 2010. Under her leadership, Axogen has built awareness of the patient quality of life impact related to nerve damage and has created the market for nerve repair. She has driven the diversification of Axogen’s portfolio to address nerve connection, protection, and termination with multiple nerve repair product launches and has led the work to develop a unique regulatory strategy for Avance with a planned filing of a BLA in the second quarter of this year.
お知らせ • Dec 27Axogen, Inc. Appoints Kathy Weiler to its Board of DirectorsAxogen, Inc. announced the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board’s Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. Weiler is the Executive Vice President, Chief Commercial and Growth Officer at Amwell. Weiler oversees the company’s growth strategy, driving strategic initiatives and leading business development, sales and account management, commercial enablement, marketing, and strategic and channel partnership teams. Prior to Amwell, Weiler served as Chief Consumer Officer at Optum, where she led consumerism across the enterprise. Preceding that, she was Chief Consumer Strategy Officer at UnitedHealth Group and the Chief Marketing and Experience Officer of Optum Health, leading marketing efforts for Optum Care and Optum’s Population Health Solutions, Complex Care Management, Medical Benefits Management, Behavioral Health, Prevention and Financial Services businesses. Weiler also served as Chief Marketing and Product Officer at Blue Cross and Blue Shield of Massachusetts, where she drove strategic growth and retention business objectives. Weiler spent her earlier career with multiple financial services organizations. She was Chief Marketing Officer of Fidelity Investments FAS business and held senior marketing leadership roles at BNY Mellon/Pershing and The Hartford. Weiler holds a B.A. from Bowdoin College and an M.A. in International Economics and Finance from Brandeis University.
Recent Insider Transactions • Dec 14Insider recently sold €87k worth of stockOn the 11th of December, Peter Mariani sold around 13k shares on-market at roughly €6.99 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €317k more than they bought in the last 12 months.
お知らせ • Dec 06AxoGen, Inc. Announces CFO ChangesAxogen, Inc. announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately. A senior finance executive with more than 20 years of experience primarily in the life sciences industry, he replaces Peter Mariani, who will depart Axogen following a brief transition period. The move aligns the executive team with the Company’s financial management and investor relations needs going forward as Axogen focuses on continued revenue growth across both business categories while driving toward being cash flow positive and profitable. Mr. Naor has diverse finance and operations leadership experience with public and private pharma, life sciences, and medtech companies worldwide. In previous roles, he managed global organizations with up to $2.5 billion in sales and built top-performing finance & accounting, IR, legal, contracting & pricing, IT, and big data analytics functions. Mr. Naor has served as the CFO of Arbor Pharmaceuticals and supported its strategic pivot. He was also the CFO U.S./Americas of Mölnlycke Healthcare, where he played a pivotal role in its growth and profitability improvement and was the founder of UCB’s global Portfolio Management and Resource Allocation function, as well as the company’s U.S. CFO. Earlier in his career, he held several finance leadership positions with AstraZeneca, served as a financial consultant and investment banker, worked as an auditor with KPMG, and practiced commercial law. He continues to advise and serve as a board member for emerging life sciences and technology companies. Mr. Naor holds a Master of Business Administration from IMD Business School in Switzerland, a master’s degree in law (LL.M.) from Hamburg University in Germany, and bachelor’s degrees in law (LL.B.) and in accounting from the Tel-Aviv University in Israel. Mr. Naor is also a CFA charter holder.
Reported Earnings • Nov 09Third quarter 2023 earnings released: US$0.095 loss per share (vs US$0.10 loss in 3Q 2022)Third quarter 2023 results: US$0.095 loss per share (improved from US$0.10 loss in 3Q 2022). Revenue: US$41.3m (up 12% from 3Q 2022). Net loss: US$4.09m (loss narrowed 5.3% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • Nov 08Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023AxoGen, Inc. provided revenue guidance for the full-year 2023. For the year, the company maintaining full-year 2023 revenue guidance in the range of $154 million to $159 million, which represents annual growth of 11% - 15%.
お知らせ • Oct 19AxoGen, Inc. to Report Q3, 2023 Results on Nov 07, 2023AxoGen, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023
お知らせ • Sep 06Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve ProtectorAxogen, Inc. announced the full launch of Axoguard HA+ Nerve Protector. Axoguard HA+ Nerve Protector is a proprietary nerve protection device uniquely designed to provide both short- and long-term protection for peripheral nerve injuries. The device is comprised of a processed porcine submucosa extracellular matrix base layer with a hyaluronate-alginate gel coating. The gel layer facilitates enhanced nerve gliding to aid in minimizing soft tissue attachments, while the base layer is remodeled into a long-term protective tissue layer. The nerve protection category covers a wide range of injuries and defects, including nerve compression, crush, and complex traumatic injuries. The diversity of these injury types and their anatomical locations present unique challenges for both the surgeon and the patient. Optimizing outcomes requires targeted solutions to adequately address the nerve and the surrounding environment throughout the healing process.
Recent Insider Transactions • Aug 20Independent Director recently bought €56k worth of stockOn the 16th of August, Guido Neels bought around 10k shares on-market at roughly €5.60 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €349k more in shares than they bought in the last 12 months.
New Risk • Aug 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Significant insider selling over the past 3 months (€405k sold).
お知らせ • Aug 09Axogen, Inc. Provides Revenue Guidance for the Year 2023AxoGen, Inc. Provided revenue guidance for the year 2023. For the full year, the company provides revenue in the range of $154 million to $159 million which represents annual growth of 11% - 15%.
Breakeven Date Change • Aug 08Forecast to breakeven in 2025The 5 analysts covering AxoGen expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 22% per year to 2024. The company is expected to make a profit of US$15.0m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
お知らせ • Jul 28+ 1 more updateAxoGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023AxoGen, Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2023
Recent Insider Transactions • Jun 07Director recently sold €341k worth of stockOn the 1st of June, Gregory Freitag sold around 42k shares on-market at roughly €8.12 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €405k more than they bought in the last 12 months.
Recent Insider Transactions • May 25Director recently sold €64k worth of stockOn the 23rd of May, Gregory Freitag sold around 7k shares on-market at roughly €8.56 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • May 10AxoGen, Inc. Provides Earnings Guidance for the Full-Year 2023AxoGen, Inc. provided earnings guidance for the full-year 2023. For the year, the company expects revenue to be in the range of $154 million to $159 million.
Reported Earnings • May 10First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.27 loss in 1Q 2022)First quarter 2023 results: US$0.17 loss per share (improved from US$0.27 loss in 1Q 2022). Revenue: US$36.7m (up 18% from 1Q 2022). Net loss: US$7.07m (loss narrowed 38% from 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
Breakeven Date Change • Mar 28No longer forecast to breakevenThe 5 analysts covering AxoGen no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$13.6m in 2025. New consensus forecast suggests the company will make a loss of US$1.93m in 2025.
Breakeven Date Change • Mar 16No longer forecast to breakevenThe 5 analysts covering AxoGen no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$13.6m in 2025. New consensus forecast suggests the company will make a loss of US$1.47m in 2025.
Reported Earnings • Mar 15Full year 2022 earnings released: US$0.69 loss per share (vs US$0.66 loss in FY 2021)Full year 2022 results: US$0.69 loss per share (further deteriorated from US$0.66 loss in FY 2021). Revenue: US$138.6m (up 8.8% from FY 2021). Net loss: US$28.9m (loss widened 7.3% from FY 2021). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 6% per year.
お知らせ • Feb 14Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing OfficerAxogen, Inc. announced the appointment of Jens Schroeder Kemp to the newly created role of Chief Marketing Officer. Kemp brings more than 20 years of strategic marketing, sales, and business development experience in high-growing medical technology. As a member of the Axogen executive leadership team, Kemp will report directly to Karen Zaderej, Chairman, CEO and President, and will oversee the development and execution of the company’s marketing strategies. Mr. Kemp most recently served as Vice President of Marketing for Ambu Inc, where he led Ambu’s marketing efforts to create the single use endoscopy market across multiple clinical applications. Following Ambu’s acquisition of King Systems in 2012, Mr. Kemp developed and scaled the US marketing function with new capabilities in health economics and market access, market development and digital marketing. Across more than 15 years at Ambu, he had multiple roles in business development and marketing, and served as a member of the Global Management Team. Prior to Ambu, Mr. Kemp was a management consultant at PERA (Production and Engineering Research Association), where his role included sales, marketing, and innovation strategies for medical device and renewable energy products. Previously, he was co-founder of an artificial intelligence decision support software company Mindgroup ApS. Mr. Kemp has a bachelor’s degree in business administration, and a master’s degree in international marketing and management, both from Copenhagen Business School.
お知らせ • Jan 10+ 1 more updateAxoGen, Inc. to Report Q4, 2022 Results on Mar 14, 2023AxoGen, Inc. announced that they will report Q4, 2022 results on Mar 14, 2023
Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 5 analysts covering AxoGen expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$9.65m in 2025. Average annual earnings growth of 56% is required to achieve expected profit on schedule.
Reported Earnings • Nov 09Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.17 loss in 3Q 2021)Third quarter 2022 results: US$0.10 loss per share (improved from US$0.17 loss in 3Q 2021). Revenue: US$37.0m (up 18% from 3Q 2021). Net loss: US$4.32m (loss narrowed 40% from 3Q 2021). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Nov 09AxoGen, Inc. Updates Earnings Guidance for the Full Year 2022AxoGen, Inc. updated earnings guidance for the full year 2022. For the year, the company is narrowing the range of annual revenue guidance and expects revenue to be in the range of $137.5 million to $140.0 million versus the prior range of $135.0 million to $142.0 million. Full-year 2022 gross margin is expected to be above 80%.
お知らせ • Nov 01Axogen, Inc. Announces Directorate ChangesAxogen, Inc. announced that effective December 13, 2022, Adrian Tyndall, M.D., MPH, FACEP has been appointed as an independent member to the company's board of directors and will serve on the Quality, Compliance, and Portfolio Management Committee. The company also announced that Mark Gold, M.D. a founding director, will retire from the board of directors on the Effective Date. Dr. Gold will continue to serve the Board of Directors until that time. Joseph "Adrian" Tyndall, MD, MPH, FACEP is a recognized leader in emergency medicine, educational leadership and research and is currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine. Previously, Dr. Tyndall spent more than 13 years as Professor, Emergency Medicine Department Chair, Trauma Researcher and Interim Dean and Associate Vice President at the University of Florida College of Medicine and UF Health. A graduate of the University of Maryland School of Medicine including the emergency medicine residency program at the University of Maryland Medical System, Dr. Tyndall received a master's degree in Health Services Management and Health Policy from Columbia University, and a bachelor's degree in Chemistry from The George Washington University. He is board-certified in emergency medicine by the American Board of Emergency Medicine and an American College of Emergency Physicians Fellow. Dr. Tyndall is the current President of the Society for Academic Emergency Medicine Foundation and was also recently elected to serve a two year term on the administrative board of the Council of Deans of the Association of American Medical Colleges (AAMC). He has researched and published on traumatic and ischemic brain injuries, is an editor for a leading emergency medicine reference textbook and is known worldwide in the field of emergency medicine.
お知らせ • Oct 21AxoGen, Inc. to Report Q3, 2022 Results on Nov 08, 2022AxoGen, Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 08, 2022
Reported Earnings • Aug 04Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.19 loss in 2Q 2021)Second quarter 2022 results: US$0.18 loss per share (up from US$0.19 loss in 2Q 2021). Revenue: US$34.5m (up 2.6% from 2Q 2021). Net loss: US$7.74m (loss narrowed 2.0% from 2Q 2021). Over the next year, revenue is forecast to grow 17%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 3% per year.
お知らせ • Jul 19+ 2 more updatesEric Sandberg, Current Chief Commercial Officer Will Be Leaving AxoGen, IncAxoGen, Inc. announced that the company is making certain changes to its commercial organization designed to leverage the strength of its growing portfolio of clinical data and support innovation of advanced nerve repair solutions. As a result of these changes, the sales organization will report directly to Karen Zaderej, Axogen’s chairman, CEO, and president, and the company anticipates appointing a chief marketing officer in the coming months. Eric Sandberg, the Company’s current chief commercial officer will be leaving the organization effective July 19, 2022.
お知らせ • Jul 12Axogen, Inc. Appoints William Burke to Board of DirectorsAxogen, Inc. announced that, effective July 11, 2022, William Burke has been appointed to its Board of Directors and will serve as chair of the Audit Committee. Mr. Burke is a recognized finance leader in the medical technology industry with more than 25 years of experience in senior leadership positions, including at Haemonetics, Medtronic, and Covidien. Burke was the executive vice president, chief financial officer of Haemonetics Corporation from August 2016 to June 2022 with responsibility for the global finance organization including investor relations. From July 2014 to July 2016, Burke served as chief integration officer and vice president, Integration for Medtronic plc and was a member of its executive committee. In that role, he was responsible for ensuring the successful integration of Medtronic with Covidien plc following its acquisition by Medtronic. Prior to joining Medtronic, Burke spent more than 20 years in finance and business development leadership roles at Covidien, including chief financial officer for Covidien Europe based in Zurich, vice president of Corporate Strategy and Portfolio Management and vice president of Financial Planning and Analysis. He also previously held key positions within Tyco Healthcare, including the financial controller of Valleylab, managing director of the Covidien Group in Switzerland, and international controller. He began his career as an auditor with KPMG. He currently serves on the board of directors of MiroMatrix. He received his Bachelor of Science degree in Business Administration from Bryant College.
Reported Earnings • May 06First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 1Q 2021)First quarter 2022 results: US$0.27 loss per share (down from US$0.16 loss in 1Q 2021). Revenue: US$31.0m (flat on 1Q 2021). Net loss: US$11.5m (loss widened 72% from 1Q 2021). Over the next year, revenue is forecast to grow 13%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • May 05+ 1 more updateAxoGen, Inc. Provides Earnings Guidance for the Full Year of 2022AxoGen, Inc. provided earnings guidance for the full year of 2022. For the year, the company continues to expect 2022 revenue will be in the range of $135.0 million to $142.0 million. This represents approximately 10% to 15% growth over 2021 revenue excluding the impact of $4.1 million of Avive revenue in 2021. Full-year 2022 gross margin is expected to be above 80%.
お知らせ • Apr 15AxoGen, Inc., Annual General Meeting, May 25, 2022AxoGen, Inc., Annual General Meeting, May 25, 2022, at 08:15 Eastern Daylight. Agenda: To consider electing eight members to board of directors to hold office for the ensuing year and until their successors are elected and qualified; to consider ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2022; to consider approving compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement; to consider amendments; and to consider similar matters.
お知らせ • Apr 14AxoGen, Inc. to Report Q1, 2022 Results on May 04, 2022AxoGen, Inc. announced that they will report Q1, 2022 results After-Market on May 04, 2022
お知らせ • Apr 03AxoGen, Inc. Announces Board ChangesOn March 29, 2022, Quentin S. Blackford notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Audit Committee and Compensation Committee, effective as of 11:59 PM EST on March 30, 2022. Mr. Blackford’s decision to resign was not associated with or attributable to any dispute or disagreement with the Company, its management or the Board on any matter relating to the Company’s operations, policies or practices, or otherwise. To fill the vacancies on the Board committees created by Mr. Blackford’s departure, the Board has, in each case, effective as of March 30, 2022 (i) appointed John H. Johnson to serve on the Audit Committee as its chair, and (ii) appointed Alan M. Levine to serve on the Compensation Committee.
Reported Earnings • Feb 24Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.66 loss per share (down from US$0.59 loss in FY 2020). Revenue: US$127.4m (up 13% from FY 2020). Net loss: US$27.0m (loss widened 13% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • Jan 12AxoGen, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021AxoGen, Inc. provided earnings guidance for the fourth quarter and full year of 2021. Fourth quarter revenue is expected to be approximately $31.5 million, a 3% decrease compared to fourth-quarter 2020 revenue of $32.5 million.Management now expects 2021 revenue to be approximately $127.3 million and continues to expect full-year 2021.
